00009276538-K2024-09-05false00009276532024-09-052024-09-050000927653us-gaap:CommonStockMember2024-09-052024-09-050000927653mck:A1.500NotesDue2025Member2024-09-052024-09-050000927653mck:A1.625NotesDue2026Member2024-09-052024-09-050000927653mck:A3.125NotesDue2029Member2024-09-052024-09-05

 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of report (Date of earliest event reported): September 5, 2024
mckessonlogoa04.jpg
McKESSON CORPORATION
(Exact Name of Registrant as Specified in Charter)
Delaware1-1325294-3207296
(State or Other Jurisdiction
of Incorporation)		(Commission
File Number)		(I.R.S. Employer
Identification No.)
6555 State Hwy 161
Irving, TX 75039
(Address of Principal Executive Offices, and Zip Code)
(972) 446-4800
Registrant’s Telephone Number, Including Area Code
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communication pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communication pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading
Symbol(s)		Name of each exchange
on which registered
Common stock, $0.01 par valueMCKNew York Stock Exchange
1.500% Notes due 2025MCK25New York Stock Exchange
1.625% Notes due 2026MCK26New York Stock Exchange
3.125% Notes due 2029MCK29New York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging growth company  ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐


Item 7.01
Regulation FD Disclosure.

McKesson Corporation participated in the Wells Fargo 2024 Healthcare Conference on September 5, 2024, as previously noticed in the company’s August 7, 2024 earnings release and on its investor relations website investor.mckesson.com.

During the conference webcast, McKesson affirmed fiscal 2025 full year Adjusted Earnings per Diluted Share guidance in the range of $31.75 to $32.55. McKesson also indicated it anticipates second quarter fiscal 2025 Adjusted earnings per Diluted Share to be in the range of $6.70 to $7.00.

Non-GAAP Financial Measures

Adjusted Earnings per Diluted Share (Non-GAAP): We define Adjusted Earnings per Diluted Share as GAAP earnings per diluted common share attributable to McKesson, excluding per share impacts of amortization of acquisition-related intangibles, transaction-related expenses and adjustments, LIFO inventory-related adjustments, gains from antitrust legal settlements, restructuring, impairment, and related charges, claims and litigation charges, other adjustments, as well as the related income tax effects for each of these items, as applicable, divided by diluted weighted-average shares outstanding.

McKesson does not provide forward-looking guidance on a GAAP basis as the company is unable to provide a quantitative reconciliation of forward-looking Non-GAAP measures to the most directly comparable forward-looking GAAP measure, without unreasonable effort. McKesson cannot reasonably forecast LIFO inventory-related adjustments, certain litigation loss and gain contingencies, restructuring, impairment and related charges, and other adjustments, which are difficult to predict and estimate. These items are generally uncertain and depend on various factors, many of which are beyond the company's control, and as such, any associated estimate and its impact on GAAP performance could vary materially.

Cautionary Statements
This report contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Readers should not place undue reliance on forward-looking statements, such as financial performance forecasts, which speak only as of the date they are first made. Except to the extent required by law, we undertake no obligation to update or revise our forward-looking statements. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those projected, anticipated, or implied. Although it is not possible to predict or identify all such risks and uncertainties, we encourage investors to read the risk factors described in our publicly available filings with the Securities and Exchange Commission and news releases.

These risk factors include, but are not limited to: we experience costly and disruptive legal disputes and settlements, including regarding our role in distributing controlled substances such as opioids; we might experience losses not covered by insurance or indemnification; we are subject to frequently changing, extensive, complex, and challenging healthcare and other laws; we from time to time record significant charges from impairment to goodwill, intangibles, and other long-lived assets; we experience cybersecurity incidents that might significantly compromise our technology systems or might result in material data breaches; we may be unsuccessful in achieving our strategic growth objectives; we may be unsuccessful in our efforts to implement initiatives to reduce or optimize our costs; we are impacted by customer purchase reductions, contract non-renewals, payment defaults, and bankruptcies; our contracts with government entities involve future funding and compliance risks; we might be harmed by changes in our relationships or contracts with suppliers; our use of third-party data is subject to limitations that could impede the growth of our data services business; we might be adversely impacted by healthcare reform such as changes in pricing and reimbursement models; we might be adversely impacted by competition and industry consolidation; we are adversely impacted by changes or disruptions in product supply and have had difficulties in sourcing or selling products due to a variety of causes; we might be adversely impacted as a result of our distribution of generic pharmaceuticals; we might be adversely impacted by changes in the economic environments in which we operate; changes affecting capital and credit markets might impede access to credit, increase borrowing costs, and disrupt banking services for us and our customers and suppliers and might impair the financial soundness of our customers and suppliers; we might be adversely impacted by changes in tax legislation or challenges to our tax positions; we might be adversely impacted by events outside of our control, such as widespread public health issues, natural disasters, political events and other catastrophic events; we may be adversely affected by global climate change or by legal, regulatory, or market responses to such change; and governance issues and regulations, including those related to social issues, climate change, and sustainability, and stakeholder response thereto may have an adverse effect on our business, financial condition, and results of operations and damage our reputation.


SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: September 5, 2024
 
McKesson Corporation
By:/s/ Britt J. Vitalone
Britt J. Vitalone
Executive Vice President and
Chief Financial Officer


v3.24.2.u1
Cover Page
Sep. 05, 2024
Entity Information [Line Items]  
Document Type 8-K
Document Period End Date Sep. 05, 2024
Entity Registrant Name McKESSON CORPORATION
Entity Central Index Key 0000927653
Entity File Number 1-13252
Entity Incorporation, State or Country Code DE
Entity Tax Identification Number 94-3207296
Entity Address, Address Line One 6555 State Hwy 161
Entity Address, City or Town Irving
Entity Address, State or Province TX
Entity Address, Postal Zip Code 75039
City Area Code 972
Local Phone Number 446-4800
Written Communications false
Soliciting Material false
Pre-commencement Issuer Tender Offer false
Pre-commencement Tender Offer false
Entity Emerging Growth Company false
Amendment Flag false
Common Stock [Member]  
Entity Information [Line Items]  
Security Exchange Name NYSE
Title of 12(b) Security Common stock, $0.01 par value
Trading Symbol MCK
1.500% Notes Due 2025 [Member]  
Entity Information [Line Items]  
Security Exchange Name NYSE
Title of 12(b) Security 1.500% Notes due 2025
Trading Symbol MCK25
1.625% Notes Due 2026 [Member]  
Entity Information [Line Items]  
Security Exchange Name NYSE
Title of 12(b) Security 1.625% Notes due 2026
Trading Symbol MCK26
3.125% Notes Due 2029 [Member]  
Entity Information [Line Items]  
Security Exchange Name NYSE
Title of 12(b) Security 3.125% Notes due 2029
Trading Symbol MCK29
McKesson (NYSE:MCK)
Historical Stock Chart
From Nov 2024 to Dec 2024 Click Here for more McKesson Charts.
McKesson (NYSE:MCK)
Historical Stock Chart
From Dec 2023 to Dec 2024 Click Here for more McKesson Charts.